Premium
Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis
Author(s) -
OforiAsenso Richard,
Sahle Berhe W.,
Chin Ken Lee,
Mazidi Mohsen,
Ademi Zanfina,
De Bruin Marie Louise,
Liew Danny
Publication year - 2021
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.3350
Subject(s) - medicine , meta analysis , persistence (discontinuity) , confidence interval , observational study , medline , biology , geotechnical engineering , engineering , biochemistry
Aims Despite increasing prescription of sodium glucose co‐transporter 2 (SGLT2) inhibitors, there is limited insight of the patterns of use among patients with diabetes prescribed these drugs. This study aimed to summarize available real‐world data on the adherence and persistence to SGLT2 inhibitors. Materials and Methods A systematic review for observational studies reporting the adherence and persistence to SGLT2 inhibitors was performed in Medline, Embase, and Web of Science from their inception to October 2019. Data were analysed via random‐effects meta‐analysis. Results A total of 22 studies (31 cohorts) comprising 123 854 individuals prescribed SGLT2 inhibitors from eight countries were included. The pooled mean proportions of days covered [PDC] at six months and one year were 0.77 (95% confidence interval [CI] 0.72‐0.82) and 0.72 (95% CI 0.66‐0.77), respectively. The pooled proportions adherent (PDC ≥0.80) at six months and one year were 59.5% (95% CI 52.9‐65.9) and 49.0% (95% CI 42.3‐55.8), respectively. The pooled proportions of people persistent at six months, one year, and two years were 80.1% (95% CI 75.8‐84.0), 61.8% (95% CI 57.8‐65.7), and 45.9% (95% CI 35.5‐56.5), respectively. When persistence was defined as the absence of ≥90‐days gap, the equivalent pooled proportions persistent were 81.5% (95% CI 73.1‐88.6), 58.9% (95% CI 53.1‐64.6), and 34.7% (95% CI 33.6‐35.8). Adherence and persistence appeared to vary across different SGLT2 inhibitors. Conclusions Real‐world adherence and persistence to SGLT2 inhibitors is poor. Hence, targets for improving treatment adherence and persistence need to be identified and appropriate interventions implemented.